Costimulatory Blockade and Use of mTOR Inhibitors: Avoiding Injury Part 2

David Wojciechowski, Flavio Vincenti

Research output: Contribution to journalReview articlepeer-review

Abstract

Kidney transplantation immunosuppression relies on a calcineurin inhibitor backbone. Calcineurin inhibitors have reduced early-acute rejection rates but failed to improve long-term allograft survival. Their nephrotoxicity has shifted the focus of investigation to calcineurin inhibitor–free regimens. Costimulation blockade with belatacept, a second generation, higher avidity variant of CTLA4-Ig, has emerged as part of a calcineurin inhibitor–free regimen. Belatacept has demonstrated superior glomerular filtration rate compared with calcineurin inhibitors albeit with an increased risk of early and histologically severe rejection. Focus on optimizing the belatacept regimen to reduce the acute rejection rate while maintaining superior renal function is underway. Belatacept has also been utilized as part of a calcineurin inhibitor–free conversion strategy in stable renal transplant recipients and has demonstrated superior improvement in glomerular filtration rate with conversion vs calcineurin inhibitor continuation. Additional work is underway to better define the role of belatacept in patients on calcineurin inhibitors with allograft dysfunction not due to rejection.

Original languageEnglish (US)
Pages (from-to)306-311
Number of pages6
JournalAdvances in Chronic Kidney Disease
Volume23
Issue number5
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Keywords

  • Belatacept
  • Costimulation blockade
  • mTOR inhibitors
  • Renal injury

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Costimulatory Blockade and Use of mTOR Inhibitors: Avoiding Injury Part 2'. Together they form a unique fingerprint.

Cite this